Viatris to Buy Pacira BioSciences for 1.65 Billion
Viatris agreed to acquire Pacira BioSciences for 1.65 billion dollars in cash to expand its portfolio of non-opioid pain treatments. The transaction adds established drugs Exparel and Zilretta to Viatris. The deal is expected to close by the end of 2026.
Xurve View
Insights:
Xurve View
VIATRIS INC will acquire PACIRA BIOSCIENCES INC for $1.65B in cash, adding two non-opioid pain treatments to its branded drug portfolio. The offer price of $36.50 per share represents a 44.8% premium to the stock's previous close. The transaction marks Viatris' latest push to expand higher-value patent-protected medicines beyond its core generics business.
